10x Genomics CSO sells 13,818 shares for taxes

10x Genomics, Inc. (TXG) reported that Benjamin J. Hindson, its President and Chief Scientific Officer and a director, sold 13,818 shares of Class A common stock on August 24, 2026.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) reported that Benjamin J. Hindson, its President and Chief Scientific Officer and a director, sold 13,818 shares of Class A common stock on August 24, 2026. The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and Hindson held 488,182 shares directly after the transaction. The sale price reflected a weighted average of $63.0236 per share from multiple trades between $63.0088 and $63.78.

Insider Trade Summary

Net Seller: 13,818 shares

Net Sell 1 txn

Insider Hindson Benjamin J.

Role See Remarks

Sold 13,818 shs ($871K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	13,818	$63.0236	$871K

Holdings After Transaction: Class A Common Stock — 488,182 shares (Direct)

Footnotes (2)

1. F1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
2. F2. This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Shares sold: 13,818 shares of Class A Common Stock Weighted average sale price: $63.0236 per share Shares held after transaction: 488,182 shares +1 more

4 metrics

Shares sold 13,818 shares of Class A Common Stock Sale on August 24, 2026 to cover tax withholding obligations

Weighted average sale price $63.0236 per share Multiple trades ranging from $63.0088 to $63.78

Shares held after transaction 488,182 shares Direct ownership by Benjamin J. Hindson following the sale

Price range of trades $63.0088–$63.78 per share Individual trade prices within the reported weighted average sale

Key Terms

restricted stock units, tax withholding obligations, weighted average sale price

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold to cover tax withholding obligations in connection with the vesting"

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TXG report for Benjamin J. Hindson?

TXG reported that Benjamin J. Hindson sold 13,818 shares of Class A common stock on August 24, 2026, in connection with tax withholding obligations from vesting restricted stock units. After this sale, he held 488,182 shares directly.

At what price were Benjamin J. Hindson’s TXG shares sold?

The reported sale used a weighted average price of $63.0236 per share. The transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78 per share, inclusive.

Why did Benjamin J. Hindson sell TXG stock in this Form 4?

The Form 4 states the 13,818 shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, indicating a tax-related sale rather than a discretionary open-market liquidation of holdings.

How many TXG shares does Benjamin J. Hindson hold after this transaction?

Following the sale, Benjamin J. Hindson directly held 488,182 shares of 10x Genomics, Inc. Class A common stock, as reported in the Form 4.

Was Benjamin J. Hindson’s TXG stock sale under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote stating the trades were made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:44 PM EDT Accepted by SEC EDGAR 08/26/2026 - 04:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hindson Benjamin J.

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/24/2026		S(1)		13,818	D	$63.0236(2)	488,182	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

2. This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Remarks:

Title: President and Chief Scientific Officer

	/s/ Randy Wu, as Attorney-in-Fact for Benjamin J. Hindson	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)